Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069556 · ClinicalTrials.gov registry record
ColoSense Post-Approval Study
A clinical trial of Colorectal Cancer (Diagnosis), sponsored by Geneoscopy.
- Recruiting
- Registry status
- 12,500
- Enrollment target
- 1
- Study location
NCT07069556 is a study of Colorectal Cancer (Diagnosis) that is actively recruiting participants, run by Geneoscopy. The registered enrollment target is 12,500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07069556, a study of Colorectal Cancer (Diagnosis), is actively recruiting participants, sponsored by Geneoscopy.
- RECRUITING
- Registry status
- 12,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
Conditions Studied
Interventions
- DEVICE ColoSense
Study Locations (1)
Missouri
- Decentralized Study - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,500 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2030-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07069556
The ClinicalTrials.gov registry entry for NCT07069556 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geneoscopy, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which ColoSense is the first listed.
NCT07069556 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07069556 about?
NCT07069556 is a clinical study titled "ColoSense Post-Approval Study". The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of Co...
What is the current status of trial NCT07069556?
This trial is currently recruiting. The enrollment target is 12,500 participants. The study started on 2025-09-05. Estimated completion is 2030-09-01.
What conditions does trial NCT07069556 study?
This clinical trial studies the following conditions: Colorectal Cancer (Diagnosis).
What interventions are being tested in trial NCT07069556?
The interventions under investigation include: ColoSense (DEVICE).
Who is sponsoring clinical trial NCT07069556?
This trial is sponsored by Geneoscopy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069556 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.